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Toxoplasma gondii is an obligate intracellular parasite, capable of infecting humans and other 
warm-blooded animals. It is typically associated with the adequately named infection, 
toxoplasmosis. 
The aim of the present work was to develop serotyping by selecting different synthetic GRA8 
C-terminal polymorphic peptides with 64 human serum samples (of known strain types) to 
determine the peptides’ ability to differentiate strain types of T. gondii (I, II, III and atypical). 
Serotyping is a typing method consisting of an immunoenzymatic assay (enzyme-linked 
immunosorbent assay [ELISA]) using synthetic polymorphic peptides derived from 
Toxoplasma gondii antigens. 
Sera samples were processed through indirect ELISA and the colour product formed measured 
by absorbance at 415 nm. Data obtained was processed in a Receiver Operating Characteristic 
(ROC) curve to determine the sensibility and specificity of each peptide. 
Of the four GRA8II peptides used (217, 221, 246 and 258), only GRA8II 221 proved to have 
some ability to differentiate strains of type II from non-type II with an 85,8% probability of 
doing so. However, with such poor results for the remaining three peptides (all three with a 
probability of successfully distinguish between different strains types under 60%), GRA8 may 
not be an ideal peptide to be used for serotyping. 
 









Toxoplasma gondii é um parasita intracelular obrigatório, capaz de infetar humanos e outros 
animais de sangue quente. T. gondii é tipicamente associado à infeção pela qual é responsável, 
designada por toxoplasmose. 
O objetivo do presente trabalho foi testar novos péptidos polimórficos de GRA8 por 
serotipagem com 64 amostras de soro humano (com linhas clonais conhecidas) para determinar 
a capacidade dos péptidos de diferenciar linhas clonais de T.gondii. 
A serotipagem é um método constituído por um ensaio imunoenzimático (ELISA) que utiliza 
péptidos polimórficos sintéticos derivados de antigénios de T. gondii. 
As amostras de soro foram processadas através de ELISA indireta e o produto de cor formado 
foi avaliado medindo a sua absorbância a 415 nm. Os dados obtidos foram processados numa 
curva Receiver Operating Characteristic (ROC) para determinar a sensibilidade e 
especificidade de cada péptido. 
Dos quatro péptidos de GRA8II usados (217, 221, 246 e 258), apenas o péptido GRA8II 211 
demonstrou ter alguma capacidade para ser usado na distinção entre estirpes tipo II de estirpes 
não-tipo II, com uma probabilidade de 85,8% de o fazer com sucesso. No entanto, os resultados 
menos satisfatórios verificados para os restantes três péptidos (todos com uma probabilidade de 
distinguir com sucesso entre tipos de estirpes abaixo de 60%) sugerem que GRA8 talvez não 
seja o péptido mais indicado para ser usado em serotipagem. 
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1.1 The Parasite: Toxoplasma gondii 
Toxoplasma gondii is an obligate intracellular parasite, capable of infecting humans and other 
warm-blooded animals. It was first discovered in a Tunisian rodent in 1908 by Nicolle and 
Manceaux. It belongs to the kingdom Protista, subkingdom Protozoa, phylum Apicomplexa, 
class Sporozoasida, subclass Coccidiasina, order Eimeriorina, family Toxoplasmatidae, genus 
Toxoplasma and species gondii (Dubey, 2010). 
T. gondii’s life cycle is heteroxenous. Sexual reproduction is exclusive to members of the 
Felidae family, T.gondii definitive hosts (being the domestic cat the most common), while 
asexual replication can occur in both definitive and intermediate hosts. Virtually, all warm-
blooded animals, including humans, can be intermediate hosts.  
There are three infective stages of T. gondii - sporozoites (protected inside oocysts), tachyzoites, 
and bradyzoites (in tissue cysts) -, connected in a complex life cycle (Fig. 1). All three stages 
can infect both types of hosts (Dubey, 2010). 
 




Sexual reproduction of T.gondii begins with the ingestion of any of the three infective stages 
(due to its high resistance, tissue cysts are the most common) by the definitive host. The parasite 
then invades the epithelial cells of the small intestine lining where it will undergo several rounds 
of division and differentiate into gametocytes.  
The fusion of the gametocytes originates an oocyst that is shed into the environment with the 
host's faeces. After undergoing meiosis, oocyst produce sporozoites (Fig. 2) that, under the right 
conditions, may remain infective for up to a year in the environment (Halonen and Weiss, 
2013).  
 
The ingestion of sporozoites by any of the intermediate hosts marks the beginning of the asexual 
replication of T.gondii. After ingestion, the sporozoites go to infect the intestinal epithelium 
and differentiate into the tachyzoite stage.  
Tachyzoites (tachos = speed in Greek) are crescent-shaped cells approximately 2 by 6 μm with 
a complex internal ultrastructure (Fig. 3). They are capable of rapidly multiplying inside any 
kind of nucleated cell by endodyogeny, after which the newly formed tachyzoites exit the cell 
and disseminate throughout the host (Halonen and Weiss, 2013). While they don’t have visible 
means of locomotion (like cilia or flagella), tachyzoites can move by gliding; their motility is 
powered by an actin-myosin motor complex on the inner membrane (Blader et al., 2015; Dubey, 
Figure 2: Schematization of a Sporozoite (Dubey, 2010). 
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2010). The activation of the host’s immune system induces T. gondii to differentiate tachyzoites 
into bradyzoites and form tissue cysts.  
Bradyzoites (brady = slow in Greek) represent the persistent stage of infection, as they may 
remain with the host through its life span. While tachyzoites aren’t specific to a type of cell, 
bradyzoites are predominantly found in cerebral and muscle tissue (Robert-Gangneux and 
Dardé, 2012). Upon the loss of an immune response, bradyzoites can differentiate back into 
tachyzoites and resume their propagation through the host’s cells. 
Within the host cells, bradyzoites can be found inside tissue cysts. Whereas a bradyzoite in 
itself has similar dimensions to a tachyzoite, its cysts can reach up to be 100μm long and 
harbour thousands of bradyzoites (Dubey, 2010). 
 
Figure 3: Schematic drawing of a Tachyzoite and a Bradyzoite, respectively (Dubey, 2010). 
 
Despite having a heteroxenous life cycle, sexual reproduction of T.gondii it’s not required for 





1.2 Toxoplasmosis  
Toxoplasma gondii is typically associated with the adequately named infection, toxoplasmosis. 
While the microorganism itself was first discovered in 1908, it was only successfully isolated 
from humans in 1939 by Wolf and colleagues, and only two years later, in 1941, was it proven 
by Sabin to be identical to the T.gondii that infected animals (reviewed in Dubey, 2008). 
Toxoplasmosis can be acquired through different routes (Fig. 4). The most common routes are 
through ingestion of oocysts (sporozoites) from the environment and contact with cat faeces, 
ingestion of tissue cysts (bradyzoites) in undercooked meat, and by transplacental transmission 
of tachyzoites (Dubey, 2008).  Other less common routes of transmission include accidental 
infection in laboratories while manipulating tachyzoites, blood (more specifically, transfusion 
of packed leukocytes) and bone marrow transfusions (both occurrences are theoretically 
possible if the donor was recently infected and is parasitemic at the time of sampling), as well 
as organ transplants since tachyzoites can infect all nucleated cells (Robert-Gangneux and 
Dardé, 2012). Due to such diversified routes of transmission, T. gondii can be spread from 
definitive to intermediate hosts, from intermediate to definitive hosts, as well as between 
definitive and between intermediate hosts (Tenter et al., 2000). 
Figure 4:  Sources of T. gondii infection in humans (Robert-Gangneux and Dardé, 2012). 
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In humans, T. gondii has to succeed in balancing the modification of its surrounding 
environment to support its survival and transmission and, simultaneously, avoid excessive 
tissue damage (either by the parasite, or unleashed by means of immune response) (Carruthers 
and Suzuki, 2007).  Clinical manifestations of toxoplasmosis ensue from tissue destruction 
caused by the tachyzoites’ fast-replicating stage, which could be lethal to the host (Blader et 
al., 2015). In most T. gondii’s infections however, the parasite-host homeostasis is effectively 
maintained; for this reason, an infection by T.gondii usually remains asymptomatic in 
immunocompetent patients.  
Those with clinical symptoms often experience lymphadenopathy in the head and neck region 
(axillary, inguinal, retroperitoneal and mesenteric lymph nodes may also occur); it may also be 
accompanied by fever, malaise, sore throat, rash and hepatosplenomegaly (Robert-Gangneux 
and Dardé, 2012; Halonen and Weiss, 2013). Although rarer, immunocompetent patients may 
display other more severe symptoms including encephalitis, sepsis, myocarditis, and hepatitis 
(Tenter et al., 2000). Essentially, all organs can be affected. Toxoplasmosis has also been 
associated with neuropsychiatric disorders, which suggests that latent infection may have subtle 
neurological effects (Halonen and Weiss, 2013). 
Because T. gondii‘s bradyzoites may remain within the host through its life span - usually in a 
latent, subclinical infection -, there is a possibility of a spontaneous reactivation by means of 
differentiation of bradyzoites back to tachyzoites.  
Whereas a functional immune system can prevent dissemination of tachyzoites, in 
immunocompromised patients (HIV/AIDS, transplants, and cancer patients) the immune 
system might be unable to respond accordingly. The chance of reactivation of latent infections 
is higher, symptoms deemed rare in immunocompetent patients are more common in 
immunocompromised individuals, and can be fatal if not recognized and promptly treated 
(Black and Boothroyd, 2000).  
As mentioned before, toxoplasmosis can also be acquired through transplacental transmission 
of tachyzoites. This is called a congenital infection and is a consequence of primary infection 
of the mother during pregnancy. The earlier in pregnancy it occurs, the less likely are 
tachyzoites to colonize placental tissue and cross the placental barrier (Robert-Gangneux and 
Dardé, 2012; Sullivan and Jeffers, 2012). During the first trimester the risk of congenital 
infection is around 10% to 15%, while during the third trimester the risk increases exponentially 
to 60%–90% (Dubey, 2010).  
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The severity of the infection is not related to the degree of symptoms of the infected mother, 
but to the stage of pregnancy in which the infection occurred – the earlier in the pregnancy it 
occurs, the worst will the consequences be. The consequences of said infection on the foetus 
vary from subclinical (although clinical symptoms may develop later in life) to severe, leading 
to foetal loss or lesions involving, predominantly, the brain and eye.  
 
1.3 Epidemiology: Prevalence of T.gondii in the World 
T. gondii has a worldwide distribution which makes its associated infection one of the most 
common in humans and warm-blooded animals. It has been documented in virtually every 
species of mammal and even on several species of birds (Dubey, 2010). Prevalence of 
toxoplasmosis is higher in warm climates and in low altitude areas. This relates to the 
environmental conditions that favour sporulation and survival of oocysts.  
Cultural habits and hygiene play an important role in the incidence of the infection, especially 
in terms of cooking and eating habits. It is estimated that about 50% to 80 % of the European 
population are infected (European Food Safety Authority (EFSA), 2016). For example, the high 
seroprevalence of toxoplasmosis in France is most likely related with eating raw or 
undercooked meat (especially pork and mutton). While in Asia - where most Asians cook their 
meat well - the seroprevalence in lower. In underdeveloped countries, the incidence of other 
parasites besides T.gondii also assures meat is cooked well prior consumption (Dubey, 2010), 
which lowers the incidence of the infection. The Centre for Disease Prevention and Control 
(CDC) estimates that, in the US, 22.5% of the population 12 years and older have been infected 
with Toxoplasma (CDC, 2015). 
Although eating habits do play an important role in T.gondii transmission, it is unknown exactly 
what proportion of infection is caused by eating raw or undercooked meat contaminated with 
tissue cysts, and what is due to oocysts on unwashed hands or vegetables. It’s also necessary to 
take into account the number and presence of the cats, climate, cultural and ethnic practices 





1.4 Laboratory Diagnosis of Toxoplasmosis 
The clinical symptoms of an infection by Toxoplasma gondii aren’t specific enough to serve as 
a definite identification, so the diagnosis of toxoplasmosis relies on laboratory techniques. 
Toxoplasmosis can be diagnosed by biologic, serologic, and histological methods, or by a 
combination of some of these. Isolation of T.gondii can be attempted from different specimens 
like secretions, excretions, body fluids, and by biopsy of tissues (such as lymph nodes or muscle 
tissue) (Dubey, 2010).  
Traditionally, detection of T.gondii relied on microscope examination. Light microscopy isn’t 
sensitive enough to provide a reliable identification, but, samples can be enriched by filtration 
or centrifugation, and stained to help distinguish parasites from host cells. However, 
microscopic diagnosis is a time consuming method, may require considerable skills for the 
obtaining of reliable results and, therefore, isn’t ideal for routine use (Liu et al., 2015).   
Isolating T. gondii by bioassay is generally considered as the gold standard for detection of T. 
gondii infection. Mice and cats are commonly used for bioassay of T. gondii (INF-gamma 
knockout mice due to high sensitivity to T. gondii infection; cats because they can be fed larger 
volumes of tissues, therefore increasing the sensitivity). Overall, a bioassay is expensive and 
time-consuming (usually requires 6 weeks). Hence why it isn’t used for screening in large-
scale. 
Setting aside the previously mentioned diagnostic methods for being too time consuming (and 
therefore not ideal for routine use), and in combination with the lack of specific clinical 
symptoms, the diagnosis of a T.gondii infection usually falls on serological assays. 
Over the years, several serologic tests have been developed - dye test (DT), modified 
agglutination test (MAT), enzyme-linked immunosorbent assays (ELISA), immunosorbent 
agglutination assay (ISAGA), indirect fluorescent antibody test (IFAT) and indirect 
haemagglutination assays (IHA) – to detect different antibody classes or antigens (Liu et al., 
2015).  
In the present work, the serologic method used was ELISA.  
ELISA is a biochemical technique used to detect the presence of an antibody or an antigen, in 




It begins with the absorption of a soluble antigen (in this case, a GRA8II peptide) onto a plastic 
surface, followed by the sera samples and the antigen-antibody reaction, enhanced by the 
addition of a secondary enzyme-linked antibody-antigen system. The reaction can be measured 
by quantification of the colour developed. In this method, the reacting enzyme is linked 
covalently to a specific antibody with the ability to recognize the target antigen. If present, the 
antibody–enzyme complex will bind to the antigen and, on addition of the substrate, the enzyme 
will catalyse the reaction generating a coloured product (Berg et al., 2015). 
 
1.5 T.gondii Antibodies and Antigens 
Antibodies, also known as immunoglobulins (Ig), are proteins produced as a part of the immune 
response to identify and neutralise pathogens. Studying the kinetics of the different antibodies 
produced, especially IgM and IgG, can help identify the stages of a T.gondii infection 
(Saadatnia and Golkar, 2012).  
IgM antibodies can be detected approximately 7 to 14 days after the onset of infection and 
persist for 1 to 6 months. IgM can remain detectable months or even years after acute infection, 
and for that reason can’t be used as a reliable indicator of acute infection.  
IgG antibodies are detectable days after the first positive IgM test, reaches a plateau within 2 to 
3 months after the onset of infection which then decreases and persists with residual titres for 
life. The appearance and increase in IgG titre confirms the existence of an infection. The 
absence of IgM while IgG is still present indicates a past infection (over six months old), but it 
cannot accurately determine the timing of the infection (Gras et al., 2004; Zhang et al., 2016).  
Antibodies can effectively identify and neutralise pathogens by recognising certain molecules 
on or within the pathogen cells responsible for the ongoing infection. These molecules are 
called antigens.   
T.gondii has several classes of antigens that, through different functions, help the parasite 
successfully infect and colonise the host. Due to their role during the process of infection, these 
proteins are often used as targets for diagnosis of toxoplasmosis. Among them, there are five 
classes of antigens that are most commonly used for their immunodominance and for being 
present in both bradyzoite and tachyzoite stages: surface antigens (SAGs), matrix antigens 
(MAGs), micronemes (MICs), rhoptries (ROPs) and dense granules (GRAs) (Kotresha and 
Noordin, 2010).    
19 
 
SAGs establish the first contact of T.gondii with the host cells as they coat, like the name 
suggest, the surface of the parasite (Blader et al., 2015). These molecules are also capable of 
inducing the host’s immune response against the tachyzoite stage to, apparently, regulate the 
virulence of the infection (Jung, 2004).   
MICs are involved in the recognition and adhesion of the parasite to the host’s cells (Mercier, 
2005; Kotresha and Noordin, 2010). They also play a role in the motility and egression (from 
the host cell, after replication) of the parasite (Blader et al., 2015).  
ROPs are discharged once MICs have successfully attached to the host cells. They are 
composed by two different substructures: rhoptry neck and rhoptry bulb. Rhoptry neck proteins 
assemble together with MICs to promote the formation of the moving junction - a tight 
apposition of the parasite and host plasma membranes visible during cell invasion that ensures 
formation of the parasitophorous vacuole membrane (Kotresha and Noordin, 2010).   
GRAs are parasitic organelles involved in cell invasion and in the intracellular survival of the 
parasite (Sousa et al., 2009). GRAs are released into the parasitophorous vacuole after invasion 
and are involved in its maturation, dictating the structure of the intravacuolar network of tubular 
membranes inside the parasitophorous vacuole where the parasite can multiply (Kotresha and 
Noordin, 2010).  
Among all the GRA proteins of T.gondii (there are, at least, 40 identified GRA so far), GRA8 
was selected for this experimental work because no previous serotyping studies on this antigen 
were found. 
GRA8 is an intron-free gene with an open reading frame of 801 bp. The sequence of GRA8 is 
composed of 267 amino acids with 12 polymorphic positions, and contains an amino terminal 
signal peptide, three degenerate proline-rich repeats in the central region and a potential 
transmembrane domain near the carboxyl terminus (Carey et al., 2000). 
GRA8 is also an immunogenic protein, acting as a marker of acute infection.  Since antibodies 
against GRA8 can be found during the acute phase of infection, IgG and IgM ELISAs with the 
GRA8 protein can be used to detect an infection of T.gondii, as well as discerning acute from 





1.6 Genotyping of Toxoplasma gondii isolates 
Genotyping studies are based on the detection of polymorphic DNA markers and are 
independent of the immune response. However, strains of T. gondii are highly similar 
antigenically which makes it harder to distinguish the type of strain just through genotyping. 
The discovery of serological epitopes that are strain specific allows genotyping to be done based 
on serological profiles (Nowakowska et al., 2006). Studies that help distinguish different types 
of strains are important to shed light into the biodiversity of the parasite and help establish a 
correlation between the genotype of T.gondii and the pathogenicity of the infection it causes in 
humans (Sousa et al., 2009). 
Genotyping methods are based on Polymerase Chain Reactions (PCRs) that can be divided in 
two groups. The first group consists of conventional, nest and real times PCRs and focuses on 
detecting T.gondii DNA; the second group consists of molecular methods including PCR- 
Restriction Fragment Length Polymorphism (RFLP), microsatellite analysis and multilocus 
sequence typing, which are mostly used for strain typing.  The methods based on PCRs are 
usually simple, sensitive and reproducible, and can be used on all clinical samples. However, 
genotyping is not standardized yet and protocols, necessary equipment, DNA markers and 
target genes may vary (Ivović et al., 2012). 
 
1.7 Serotyping of Toxoplasma gondii isolates 
The strain type is thought to play a role in the severity of an infection, and it’s usually 
determined by genotyping. However, the principal limitation of genotyping methods is that it 
is hard to obtain infective isolates (with the exception of some severe cases or in pregnant 
women with a positive amniocentesis) (Morisset et al., 2008).  It requires isolation of enough 
parasite DNA, or actual organisms, and, generally, can only be acquired from patients 
presenting clinical manifestation of the infection (Kong et al., 2003). 
Serologic methods can get around this obstacle because they target antibody classes or antigens, 
not DNA. As it has been explained previously, T.gondii is capable of inducing a strong immune 
response where antibodies (usually IgG and IgM) can remain in high concentrations for months 
up to several years, or even during the host’s whole life. The presence of said antibodies is also 
not dependent on whether the patient has symptoms of toxoplasmosis or not (Kong et al., 2003). 
21 
 
With serotyping, specific polymorphic peptides derived from T.gondii antigens can be used to 
determine strain types in non-invasive and large-scale investigations with virtually an unlimited 
number of samples.  
Several studies on this matter (such as Kong et al., 2003 and Peyron et al., 2006) have 
successfully been able to distinguish type II from non-type II infections (there is a the lack of 
differentiation between type I and type III due to high levels of homology) using synthetic 
peptides from other GRA proteins (like GRA5, GRA6 and GRA7) and other T.gondii antigens 
(Xiao et al., 2009). 
The main obstacle hindering serotyping from achieving all its potential lies in the fact that, for 
any given genetic locus, there are usually only two allelic types represented, and each archetypal 
line possesses a unique combination of those alleles (Kong et al., 2003). Which means that, for 
any given antigen, only two discriminatory peptides derived from polymorphic, 
immunodominant sites are required to determine which allele is carried by the infecting strain. 
The difficulty resides on finding these antigens and then synthetize the necessary polymorphic 
peptides. 
 
1.8 T.gondii Clonal Lineages 
T.gondii has three clonal archetypal lines: I, II and III. The origin of these three lineages seems 
to be the sexual cross between ancestral lineages. It was suggested by Boyle and colleagues 
(2006) that the origin lies on two separate crosses between ancestral versions of today’s type II 
strain and two different strains named by the authors as α and β. 
A cross between a type II (II1) and a α-strain resulted in the creation of the type I strain. The 
type III strain resulted from a cross between another type II (II3) strain and the β-strain (Fig. 5). 
The fact that identical genotypes can be found in different countries and in different hosts, also 





Figure 5: Schematization of the origin of the three T. gondii clonotypes (Boyle et al., 2006) 
 
Besides the three main strain types, several studies demonstrated the existence of strains that 
don’t fit into any of the three types. These are non-archetypal strains and are commonly called 
atypical strains. Types I, II, and III lineages are predominant in Europe and North America. 
Non-archetypal strains with atypical genotypes are more frequent in other geographical areas, 
such as Africa and South America (Sousa et al., 2008). 
 
The aim of this work was to determine if the selected polymorphic GRA 8II peptides can be 




2.1 T.gondii Sera Samples 
The sera samples used came from three distinct geographical areas: Europe, Africa and Latin 
America (France (32 sera), Portugal (3 sera), Mexico (18 sera) and Africa (11 sera)). 
Because the aim of this work was to determine if it was possible to conclude on the strain type 
trough serologic methods, all samples were previously genotyped and strain type was already 
known. Human serum samples had the following genotypes: (i) 12 cases associated with type 
I; (ii) 32 type II strains; (iii) 12 type III; (iv) 8 cases associated with atypical strains (See table 
5-1 in the Attachments section). 
20 sera samples were used as negative controls.  
2.2 GRA8II Peptides 
Four synthetic GRA8 C-terminal polymorphic peptides were used in this project. The peptides 
were named after the position in the coding sequence of the first amino acid of each peptide 
(Fig. 6 and Table 2.1-1). 
 
Table 2.2-1: Sequences of the GRA8II peptides used; underlined type indicates known polymorphic sites of each 
peptide. 
Peptide Loci aa Position Sequence 
GRA8II 217 GRA8 217-227 TTTTTRNVLLR 
GRA8II 221 GRA8 221-231 TRNVLLRTAIL 
GRA8II 246 GRA8 246-257 PLFTEGVRMFPD 
GRA8II 258 GRA8 258-269 FQYRFTVQTTQN 
GRA8II 217 GRA8II 221 
GRA8II 258 GRA8II 246 




Several trial ELISAs were performed in the beginning of this experimental work to determine 
the best methodology. Different variations of the blocking agent, and several concentrations of 
Phosphate-buffered saline (PBS)-Tween solution, IgG alkaline phosphatase antibody, peptides 
and sample dilutions were tried. The best results were obtained with the methodology presented 
below. 
 
Peptides were diluted in a carbonate/ bicarbonate buffer (0,05M; pH=9,6) to a concentration of 
30 µg/ml. Nunc Immobilizer Amino plates (Thermo Scientific, Denmark) were coated with the 
diluted peptide and incubated in the fridge overnight at 4ºC. Wells were washed three times 
with PBS and blocked with a solution of 5% Bovine serum albumin (BSA) in PBS, followed 
by incubation in humid chamber at 37ºC for one hour. The plate was washed three times with 
PBS – 0,3% Tween 20. 
 
The sera samples were diluted 1/50 in PBS – 3% BSA – 0,3% Tween 20, inoculated on the 
plate and incubated in humid chamber at 37ºC for two hours. Once completed the incubation 
period, wells were washed again three times with PBS – 0,3% Tween 20. Anti-Human IgG 
alkaline phosphatase antibody (Sigma-Aldrich, USA) was diluted 1/10000 in PBS – 0,3% 
Tween 20 and inoculated on the plate, followed by incubation in humid chamber at 37ºC for 
one hour. Well were washed again three times with PBS – 0,3% Tween 20 and developed with 
a solution of ρ-Nitrophenyl Phosphate (PNPP) in an Alkaline phosphatase buffer (NTMT) at 
37°C for 10-15 min. Absorbance of the samples was measure at 415 nm using a plate reader 
(Bio-Rad, United States). 
 
Blanks, consisting of PBS – 3% BSA – 0,3% Tween 20 + dH2O, were used on the first and last 





2.4 Statistical Analysis of Data Collected 
Statistical analysis of the data collected was performed using GraphPad Prism version 6.1 for 
Windows. 
Making use of several tools within the GraphPad Prism program, the Receiver Operating 
Characteristic (ROC) was performed, and optimal cut off values and sensitivity and specificity 




3. RESULTS AND DISCUSSION 
The absorbance results of the ELISAs can be found on the Table 5-2, in the attachment section. 
As mentioned in the Methodology section, statistical analysis was performed using GraphPad 
Prism version 6.1 for Windows.  
The Receiver Operating Characteristic (ROC) curve was performed to assess the ability of each 
peptide to differentiate the different clonal lineages of T.gondii.  
The ROC curve essentially evaluates the sensitivity and specificity of a test, or its true-positive 
rate versus false-positive rate. The higher the curve of a test, the greater is its discriminative 
ability. A test with low sensitivity but high specificity means that the positive results are reliable 
(low number of false positives), but the negatives aren’t as reliable (high false positives). The 
inverse is verified if the test has high sensitivity but low specificity (low false negatives, but 
high false positives). An ideal test has both high sensitivity and high specificity. 
The optimal cut off values can be determined with the help of the Youden Index (J), that here 
serve the purpose of helping define the maximum potential effectiveness of the peptide. 
 𝐽 = 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦𝑥 +  𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦𝑥 − 1 (3.1) 
X represents sensitivity and specificity values for each point on the ROC curve. 
The sensitivity and specificity values of each point are calculated by GraphPad Prism. By 
applying the equation (3.1) on those values, the maximum value of J can be determined; the 
values of sensitivity and specificity corresponding to said value, have a corresponding point on 
the ROC curve that is the cut-off point. The cut-off points, and respective sensitivity and 
specificity, of each peptide are presented on Table 3-1. 
Table 3-1: Youden Index, sensitivity, specificity and cut-off values for each GRA8 II peptide. 
Peptide GRA8II 217 GRA8II 221 GRA8II 246 GRA8II 258 
Youden Index 
(%) 
113,38 145,88 104 116,5 
Sensitivity (%) 59,38 71,88 50,00 62,50 
Specificity (%) 55,00 75,00 60,00 55,00 
Cut-Off Value 0,2865 0,3215 0,1870 0,3105 
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The area under the ROC curve (AUR), determined with the GraphPad Prism software, is, in 
this case, a reflection of how good each peptide is at distinguishing T.gondii type II from non-
type II sera samples. The closer the ROC curve of the peptide is of the ROC curve when 
specificity + sensitivity =1 (which translates into an uninformative test, represented in the 
graphics of Fig.7 as a dotted line), the less accurate is the peptide.   
Figure 7: ROC curves for type II sera samples, for each of the four GRA8II peptides 
 
The AUC for the GRA8II 217 peptide is 0,5828 which translates, roughly, into a 58,3% 
probability of the sera samples being of type II. Peptides GRA8II 246 and 258 present similar 
results to the GRA8II 217, with AUCs of 53,8% and 58.1%, respectively. Knowing that the 
genotype of each sample as already predetermined and the samples did belong to the type II 
genotype, adding to it the fact that the ROC curves formed by those peptides (Graphics A, C 
and D in Fig.7) stand too close to the [specificity + sensitivity =1] ROC curve, it demonstrates 
that the three peptides GRA8II 217, GRA8II 246 and GRA8II 258 cannot be used as a reliable 
tool to distinguish genotypes types. 
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GRA8II 221 has an AUC of 85,8%, and is the peptide whose ROC curve stands the furthest 
away from the [specificity + sensitivity =1] ROC curve (Graphic B in Fig. 7). Therefor it can 
be considered a good peptide (although not excellent) to be used to distinguish genotypes types. 
 
The optical density (OD) of the ELISAs was measured at 415 nm for T.gondii positive sera of 
type I (I), type II (II), type III (III), atypical (At), and T.gondii negative sera (N), for each 
GRA8II peptide (Fig.8). OD values were calculated by subtracting the OD of the peptide control 





Figure 8: Distribution of optical densities in T.gondii positive sera of type I (I), type II (II), type III (III), atypical 




Originally, besides the four GRA8II peptides, there were eight more peptides planed (four 
GRA8I and four GRAIII). However, they were not synthetized in useful time and therefore 
could not be used in this experimental work. The decision to start with the type II peptides first 
was due only to the fact that type II T.gondii is more prevalent in Europe that any of the other 
two types.  
Overall, taking into consideration the relatively low sensitivity and specificity values obtained 





4. CONCLUSIONS AND FUTURE WORK 
Peptides to be used in serotyping must be polymorphic and immunogenic, which limits the 
peptides to specific regions of the protein. Although one of the four GRA8II peptides used – 
GRA8II 221 – fared relatively well in predicting type II sera samples, the apparent limited rate 
of polymorphisms in GRA8 peptide may not make this antigen the most suited for serotyping.   
Future work on this matter may include the synthesis of the remaining eight GRA8 peptides 
initially intended to also be a part of this experimental work, to determine with certainty the 





Table 5-1: T.gondii-Positive Sera Samples Used 
SERUM ORIGIN STRAIN TYPE 
TGp-II-01 France II 
TGp-II-02 France II 
TGp-II-03 France II 
TGp-II-04 France II 
TGp-II-05 France II 
TGp-II-06 France II 
TGp-II-07 France II 
TGp-II-08 France II 
TGp-II-09 France II 
TGp-II-10 France II 
TGp-II-11 France II 
TGp-II-12 France II 
TGp-II-13 France II 
TGp-II-14 France II 
TGp-II-15 France II 
TGp-II-16 France II 
TGp-II-17 France II 
TGp-II-18 France II 
TGp-II-19 France II 
TGp-II-20 France II 
TGp-II-21 France II 
TGp-II-22 France II 
TGp-II-23 France II 
TGp-II-24 France II 
TGp-II-25 France II 
TGp-II-26 France II 
TGp-II-27 France II 
TGp-II-28 France II 
TGp-II-29 France II 
TGp-II-30 France II 
TGp-II-31 France II 
TGp-II-32 France II 
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Table 5-1: T.gondii-Positive Sera Samples Used (cont.) 
SERUM ORIGIN STRAIN TYPE 
TGp-I-01 Africa I 
TGp-I-02 Mexico I 
TGp-I-03 Mexico I 
TGp-I-04 Mexico I 
TGp-I-05 Mexico I 
TGp-I-06 Mexico I 
TGp-I-07 Mexico I 
TGp-I-08 Mexico I 
TGp-I-09 Mexico I 
TGp-I-10 Mexico I 
TGp-I-11 Mexico I 
TGp-I-12 Mexico I 
TGp-III-12 Portugal III 
TGp-III-01 Portugal III 
TGp-III-02 Portugal III 
TGp-III-03 Africa III 
TGp-III-04 Africa III 
TGp-III-05 Mexico III 
TGp-III-06 Mexico III 
TGp-III-07 Mexico III 
TGp-III-08 Mexico III 
TGp-III-09 Mexico III 
TGp-III-10 Mexico III 
TGp-III-11 Mexico III 
TGp-At-01 Africa Atypical 
TGp-At-02 Africa Atypical 
TGp-At-03 Africa Atypical 
TGp-At-04 Africa Atypical 
TGp-At-05 Africa Atypical 
TGp-At-06 Africa Atypical 
TGp-At-07 Africa Atypical 







































TGp-II-01 0,463 0,524 0,421 0,265 
TGp-II-02 0,171 0,369 1,587 0,146 
TGp-II-03 0,129 0,543 0,337 0,458 
TGp-II-04 0,281 0,474 0,613 0,185 
TGp-II-05 0,185 0,317 0,180 0,245 
TGp-II-06 0,226 0,444 0,129 0,173 
TGp-II-07 0,150 0,315 0,190 0,135 
TGp-II-08 0,267 0,264 0,139 0,223 
TGp-II-09 0,288 0,283 0,184 0,211 
TGp-II-10 0,149 0,234 0,129 0,133 
TGp-II-11 0,266 0,331 0,051 0,110 
TGp-II-12 0,287 0,267 0,078 0,157 
TGp-II-13 0,620 1,197 0,259 0,183 
TGp-II-14 0,279 2,226 0,723 0,211 
TGp-II-15 0,438 0,369 0,298 0,106 
TGp-II-16 0,392 0,244 0,396 0,126 
TGp-II-17 0,418 0,391 0,386 0,086 
TGp-II-18 0,369 0,079 0,241 0,030 
TGp-II-19 0,242 0,342 0,719 0,178 
TGp-II-20 0,127 0,809 0,243 0,094 
TGp-II-21 0,070 0,554 0,533 0,072 
TGp-II-22 0,566 0,438 0,196 0,609 
TGp-II-23 1,222 0,546 0,268 0,445 
TGp-II-24 0,507 0,220 0,198 0,359 
TGp-II-25 0,653 0,224 0,102 0,537 
TGp-II-26 0,561 0,175 0,041 0,422 
TGp-II-27 0,369 0,174 0,009 0,307 
TGp-II-28 0,288 0,201 0,197 0,364 
TGp-II-29 0,378 0,296 0,092 0,172 
TGp-II-30 0,796 0,702 0,299 0,455 
TGp-II-31 0,359 0,566 0,178 0,190 
TGp-II-32 0,614 0,643 0,400 0,407 
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TGp-I-01 0,680 0,653 0,315 0,874 
TGp-I-02 0,744 0,815 0,269 1,057 
TGp-I-03 0,484 0,290 0,171 0,317 
TGp-I-04 0,360 0,277 0,336 0,257 
TGp-I-05 0,442 0,487 0,357 0,385 
TGp-I-06 0,347 0,337 0,274 0,472 
TGp-I-07 0,316 0,243 0,087 0,264 
TGp-I-08 0,215 0,376 0,134 0,260 
TGp-I-09 0,328 0,526 0,188 0,373 
TGp-I-10 0,219 0,238 0,148 0,295 
TGp-I-11 0,387 0,221 0,172 0,986 
TGp-I-12 0,275 0,119 0,123 0,387 
TGp-III-12 0,564 0,368 0,142 0,867 
TGp-III-01 0,125 0,140 0,098 0,292 
TGp-III-02 0,252 0,118 0,019 0,692 
TGp-III-03 0,861 0,868 1,235 0,604 
TGp-III-04 0,191 0,151 0,515 0,407 
TGp-III-05 0,368 0,229 0,441 2,605 
TGp-III-06 0,680 0,268 0,446 1,867 
TGp-III-07 0,448 0,169 0,384 0,340 
TGp-III-08 0,406 0,141 0,322 0,776 
TGp-III-09 0,400 0,126 0,370 0,293 
TGp-III-10 0,491 0,211 0,394 0,574 
TGp-III-11 0,235 0,143 0,208 0,232 
TGp-At-01 0,456 0,224 0,548 0,444 
TGp-At-02 1,126 0,403 0,783 0,674 
TGp-At-03 0,564 0,205 0,548 0,323 
TGp-At-04 0,158 0,125 0,129 0,281 
TGp-At-05 0,887 0,618 0,466 0,944 
TGp-At-06 0,641 0,736 0,472 0,644 
TGp-At-07 0,456 0,587 0,381 0,444 
TGp-At-08 0,257 0,379 0,247 0,475 
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Table 5-2: Absorbance averages for each serum sample, for each peptide (cont.) 









TGn-01 0,193 0,502 0,485 0,760 
TGn-02 0,296 0,385 0,710 0,583 
TGn-03 0,526 0,163 0,129 0,470 
TGn-04 0,667 0,694 0,101 0,581 
TGn-05 0,024 0,455 0,193 0,748 
TGn-06 0,315 0,402 0,116 0,268 
TGn-07 0,101 0,197 0,267 0,757 
TGn-08 0,091 0,182 0,212 1,135 
TGn-09 0,258 0,571 0,214 0,341 
TGn-10 0,228 0,306 0,077 0,336 
TGn-11 0,378 0,276 0,244 0,455 
TGn-12 0,286 0,299 0,344 1,092 
TGn-13 0,332 0,254 0,081 0,690 
TGn-14 0,284 0,188 0,226 0,228 
TGn-15 0,694 0,938 0,057 0,482 
TGn-16 0,207 0,223 0,162 0,386 
TGn-17 0,253 0,373 0,280 0,216 
TGn-18 0,175 0,111 0,131 0,265 
TGn-19 0,359 0,359 0,463 0,593 
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